While somatic mutations in the androgen receptor are a known mechanism of acquired hormone therapy resistance in prostate cancer, somatic mutations in ESR1 have only recently been identified as an important mechanism of acquired endocrine therapy resistance in breast cancer. This evidence concerns the gene ESR1 and prostate cancer.